Study of ZIO-101 in Multiple Myeloma
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
Multiple Myeloma
DRUG: ZIO-101 (Darinaparsin)
Phase I: toxicity defined in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 12/12/03, 6 months|Phase II efficacy using EMBT criteria., 6 months|Safety, 6 months
Pharmacokinetics of ZIO-101, 6 months
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma